NCT00310037 2025-10-28
Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
Clinical Trials
34 trialsNCT05564052 2025-10-07
VEGA
Janssen Research & Development, LLC
Phase 2 Completed
NCT01415752 2025-04-08
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06656221 2024-11-19
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
Ruijin Hospital
Phase 2 Not yet recruiting
NCT04626791 2024-03-12
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT00030875 2023-08-04
Bortezomib in Treating Patients With Mantle Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00377052 2023-08-04
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT01267812 2023-07-27
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
City of Hope Medical Center
Phase 2 Completed
NCT02840539 2023-03-20
BATMAN
Seoul National University Hospital
Phase 2 Completed
NCT00114738 2022-10-10
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03617484 2020-06-22
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT00992446 2020-03-18
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00980395 2019-12-30
VCR
University of Arizona
Phase 2 Completed
NCT00581776 2019-12-17
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
University of Wisconsin, Madison
Phase 2 Completed
NCT00711828 2019-04-16
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Mayo Clinic
Phase 2 Completed
NCT00553644 2018-10-30
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00703664 2018-08-07
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02877082 2018-04-30
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
Phase 2 Terminated
NCT00201877 2018-03-12
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00376961 2017-11-06
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00837174 2017-09-19
COMBOSTAT
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT03016988 2017-01-11
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
Fujian Medical University
Phase 2 Unknown
NCT00740415 2016-03-16
ManteauRiBVD
French Innovative Leukemia Organisation
Phase 2 Completed
NCT00023764 2015-12-08
Bortezomib in Treating Patients With Lymphoproliferative Disorders
National Cancer Institute (NCI)
Phase 2 Completed
NCT01119794 2015-08-26
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Brown University
Phase 2 Terminated
NCT00871546 2015-08-07
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT01497275 2015-07-15
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Duke University
Phase 2 Terminated
NCT00958256 2015-04-13
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00513955 2014-11-05
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
University Hospital Plymouth NHS Trust
Phase 2 Completed
NCT00433537 2014-10-30
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01397591 2014-07-30
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00063713 2008-02-11
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00265928 2008-01-28
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00261612 2006-10-18
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
Medical University of Vienna
Phase 2 Unknown